MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
ANTX — AN2 Therapeutics, Inc. Common Stock
NasdaqAN2 Therapeutics, Inc. Common Stock
$5.71
+0.09(+1.60%)
- O
- 5.64
- H
- 5.99
- L
- 5.51
- V
- 451.28K
⏱️ End-of-day dataAs of Oct 2, 2026
ANTX — Latest News & Headlines
5 StoriesAN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK - Stock Titan
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK Stock Titan
AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver (NASDAQ:ANTX) - Seeking Alpha
AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver (NASDAQ:ANTX) Seeking Alpha
AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to S&P Global BMI Index - marketscreener.com
AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to S&P Global BMI Index marketscreener.com
ANTX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.66% - Tax Rate Impact - siam.in
ANTX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.66% - Tax Rate Impact siam.in
AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research - marketscreener.com
AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research marketscreener.com